Thoracic (Lung/chest)

NRG – S1914 at https://clinicaltrials.gov/study/NCT04214262

A randomized, phase III trial of induction/consolidation atelzolizumab (NSC #783608) + SBRT vs SBRT alone in high-risk, early-stage non-small-cell lung cancer (NSCLC)

Cancer Type: NSCLC, Stage I-IIA, high-risk

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

AZ TRITON – D419NL00003 at http://clinicaltrials.gov/study/NCT06008093

A Phase IIIb, Randomized, Multicenter, Open-Label Study to assess the Efficacy of Durvalumab plus Tremelimumab verus Chemotherapy for First-Line Treatment in Metastatic Non-Small Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1 or KRAS

Cancer Type: NSCLC, Stage IV, Non-Squamous and Squamous

Principal Investigator: Dr. Ryan Devine

Please contact Clinical Trials Office for more details: 561-263-5791